Core Insights - Amphastar Pharmaceuticals reported Q3 CY2025 revenue of $191.8 million, flat year on year, but exceeded Wall Street expectations by 4% [5][6] - The company's non-GAAP profit was $0.93 per share, which was 12.7% above analysts' consensus estimates [5] Company Overview - Founded in 1996, Amphastar Pharmaceuticals specializes in complex drug formulations, developing and manufacturing injectable and inhalation medications, including both generic and proprietary products [2] Revenue Growth - Over the last five years, Amphastar Pharmaceuticals achieved a compounded annual growth rate of 16.5% in sales, outperforming the average healthcare company [3] - The annualized revenue growth over the last two years was 9.7%, which is below the five-year trend but still considered respectable [4] Financial Performance - The operating margin for Q3 CY2025 was 13.2%, a significant decrease from 29.8% in the same quarter last year [5] - The average operating margin over the last five years was 23.3%, indicating the company has been efficient in its operations [8] - The operating margin has decreased by 9.3 percentage points on a two-year basis, highlighting a need for consistent profitability expansion [9] Market Outlook - Analysts project a revenue growth of 1.1% over the next 12 months, indicating potential demand headwinds for the company's products and services [6]